Antiphospholipid syndrome: an update
Identifieur interne : 000F80 ( Main/Exploration ); précédent : 000F79; suivant : 000F81Antiphospholipid syndrome: an update
Auteurs : Mira Merashli [Royaume-Uni] ; Mohammad Hassan A. Noureldine [Liban] ; Imad Uthman [Liban] ; Munther Khamashta [Royaume-Uni]Source :
- European Journal of Clinical Investigation [ 0014-2972 ] ; 2015-06.
Abstract
Background: Antiphospholipid syndrome (APS) or ‘Hughes syndrome’ is a prothrombotic disease characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). More than three decades have passed, and experts are still uncovering new pieces of this disease complex pathogenesis and management. Materials and methods: We searched in literature using MEDLINE and PubMed databases focusing on the latest development on disease pathogenesis, risk assessment of thrombosis and treatment of APS. Results: The phosphatidylinositol 3‐kinase (PI3K)–AKT‐mTORC pathway was most recently identified to have a crucial role in activating inflammation among endothelial vessel wall causing vascular lesions in APS. Additionally, new variables are being implemented to assess the risk of thrombosis in patients with APS. Global APS Score (GAPSS) utilizes cardiovascular risk factors and new autoimmune antibodies as part of the score assessment and is the most valid so far. It can be a promising tool in the future for prediction of thrombosis. Anticoagulation remains the cornerstone in APS; however, many new potential therapeutic agents are developing and are currently under investigation. Conclusions: The most recent advances in pathogenesis, risk stratification and treatment provide a platform for high yield studies with the ultimate goal of providing the optimal management to patients with APS.
Url:
DOI: 10.1111/eci.12449
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000530
- to stream Istex, to step Curation: 000530
- to stream Istex, to step Checkpoint: 000125
- to stream Main, to step Merge: 000F81
- to stream Main, to step Curation: 000F80
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiphospholipid syndrome: an update</title><author><name sortKey="Merashli, Mira" sort="Merashli, Mira" uniqKey="Merashli M" first="Mira" last="Merashli">Mira Merashli</name></author><author><name sortKey="Noureldine, Mohammad Hassan A" sort="Noureldine, Mohammad Hassan A" uniqKey="Noureldine M" first="Mohammad Hassan A." last="Noureldine">Mohammad Hassan A. Noureldine</name></author><author><name sortKey="Uthman, Imad" sort="Uthman, Imad" uniqKey="Uthman I" first="Imad" last="Uthman">Imad Uthman</name></author><author><name sortKey="Khamashta, Munther" sort="Khamashta, Munther" uniqKey="Khamashta M" first="Munther" last="Khamashta">Munther Khamashta</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AFD9D4431996A6136C0F155C2F97074B408B20D8</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/eci.12449</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-JMPPPK7T-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000530</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000530</idno><idno type="wicri:Area/Istex/Curation">000530</idno><idno type="wicri:Area/Istex/Checkpoint">000125</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000125</idno><idno type="wicri:doubleKey">0014-2972:2015:Merashli M:antiphospholipid:syndrome:an</idno><idno type="wicri:Area/Main/Merge">000F81</idno><idno type="wicri:Area/Main/Curation">000F80</idno><idno type="wicri:Area/Main/Exploration">000F80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Antiphospholipid syndrome: an update</title><author><name sortKey="Merashli, Mira" sort="Merashli, Mira" uniqKey="Merashli M" first="Mira" last="Merashli">Mira Merashli</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Rheumatology, Faculty of Medicine, The Royal London Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Noureldine, Mohammad Hassan A" sort="Noureldine, Mohammad Hassan A" uniqKey="Noureldine M" first="Mohammad Hassan A." last="Noureldine">Mohammad Hassan A. Noureldine</name><affiliation wicri:level="1"><country xml:lang="fr">Liban</country><wicri:regionArea>Faculty of Medicine, Lebanese American University Medical Center‐Rizk Hospital, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Uthman, Imad" sort="Uthman, Imad" uniqKey="Uthman I" first="Imad" last="Uthman">Imad Uthman</name><affiliation wicri:level="1"><country xml:lang="fr">Liban</country><wicri:regionArea>Division of Rheumatology, Faculty of Medicine, American University of Beirut, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Khamashta, Munther" sort="Khamashta, Munther" uniqKey="Khamashta M" first="Munther" last="Khamashta">Munther Khamashta</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Graham Hughes Lupus Research Laboratory, Division of Women's Health King's College London, The Rayne Institute, St Thomas' Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">European Journal of Clinical Investigation</title><title level="j" type="alt">EUROPEAN JOURNAL OF CLINICAL INVESTIGATION</title><idno type="ISSN">0014-2972</idno><idno type="eISSN">1365-2362</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="653">653</biblScope><biblScope unit="page" to="662">662</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2015-06">2015-06</date></imprint><idno type="ISSN">0014-2972</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2972</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Antiphospholipid syndrome (APS) or ‘Hughes syndrome’ is a prothrombotic disease characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). More than three decades have passed, and experts are still uncovering new pieces of this disease complex pathogenesis and management. Materials and methods: We searched in literature using MEDLINE and PubMed databases focusing on the latest development on disease pathogenesis, risk assessment of thrombosis and treatment of APS. Results: The phosphatidylinositol 3‐kinase (PI3K)–AKT‐mTORC pathway was most recently identified to have a crucial role in activating inflammation among endothelial vessel wall causing vascular lesions in APS. Additionally, new variables are being implemented to assess the risk of thrombosis in patients with APS. Global APS Score (GAPSS) utilizes cardiovascular risk factors and new autoimmune antibodies as part of the score assessment and is the most valid so far. It can be a promising tool in the future for prediction of thrombosis. Anticoagulation remains the cornerstone in APS; however, many new potential therapeutic agents are developing and are currently under investigation. Conclusions: The most recent advances in pathogenesis, risk stratification and treatment provide a platform for high yield studies with the ultimate goal of providing the optimal management to patients with APS.</div></front></TEI><affiliations><list><country><li>Liban</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Merashli, Mira" sort="Merashli, Mira" uniqKey="Merashli M" first="Mira" last="Merashli">Mira Merashli</name></region><name sortKey="Khamashta, Munther" sort="Khamashta, Munther" uniqKey="Khamashta M" first="Munther" last="Khamashta">Munther Khamashta</name><name sortKey="Khamashta, Munther" sort="Khamashta, Munther" uniqKey="Khamashta M" first="Munther" last="Khamashta">Munther Khamashta</name></country><country name="Liban"><noRegion><name sortKey="Noureldine, Mohammad Hassan A" sort="Noureldine, Mohammad Hassan A" uniqKey="Noureldine M" first="Mohammad Hassan A." last="Noureldine">Mohammad Hassan A. Noureldine</name></noRegion><name sortKey="Uthman, Imad" sort="Uthman, Imad" uniqKey="Uthman I" first="Imad" last="Uthman">Imad Uthman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AFD9D4431996A6136C0F155C2F97074B408B20D8
|texte= Antiphospholipid syndrome: an update
}}
| This area was generated with Dilib version V0.6.33. |  |